TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02207452

Intervention type: DEVICE
Group type: OTHER
Intervention: He-3 MRI
Description: Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).

Intervention type: DEVICE
Group type: OTHER
Intervention: He-3 MRI
Description: Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Salbutamol 5mg nebulised single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Salbutamol 5mg nebulised single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Ipratropium
Description: Ipratropium 500mcg nebulised single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Ipratropium
Description: Ipratropium 500mcg nebulised single dose

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
Study: NCT01072604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: One oral dose of new formula Aspirin Prototype 1 under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: One oral dose of new formula Aspirin Prototype 2 under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: One oral dose of Aspirin Plain Tablet under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: One oral dose of Aspirin Dry Granules under fasting conditions
Study: NCT01724632

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.
Study: NCT00038818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 Depleted Donor Lymphocyte
Study: NCT03812276

Intervention type: DEVICE
Intervention: Dental Implants
Description: Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
Study: NCT00643162

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lexapro
Description: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light touch
Description: Light touch twice a week, for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage twice a week, for 8 weeks.
Study: NCT00724087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5.5-hour bedtime
Description: 16 days with sleep allowed only during a 5.5-hour bedtime period at night

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8.5-hour bedtime
Description: 16 days with sleep allowed only during a 8.5-hour bedtime period at night
Study: NCT04296838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of Conbercept
Description: patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
Study: NCT02334462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA/Alhydrogel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TWINRIX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Study: NCT02347137

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: step-reduction
Description: reduce daily physical activity to less than 1500 steps per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: step-reduction
Description: reduce daily physical activity to less than 1500 steps per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: step-reduction
Description: reduce daily physical activity to less than 1500 steps per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: step-reduction plus resistance exercise
Description: reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: step-reduction plus resistance exercise
Description: reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: step-reduction plus resistance exercise
Description: reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
Study: NCT02083913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth supervised exercise training
Description: Endurance and strength training (3x/week during 12 weeks)
Study: NCT03021343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: colchicine given as per trial protocol
Study: NCT04319588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage
Description: After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with local anesthetic of access to thoracic drainage
Description: Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
Study: NCT02470650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir
Description: 1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir/lamivudine
Description: Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir 100 mg recovered tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 300mg (Epivir) 1 recovered tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rilpivirine
Description: rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
Study: NCT02546206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Yoghurt
Description: Probiotic yoghurt consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Natural Yoghurt
Description: Natural yoghurt consumption
Study: NCT00975780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Oral Care
Description: oral brushing plus oral chlorhexidine plus upright feeding positioning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual oral care
Description: Usual oral care and feeding positioning
Study: NCT01056016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Collaborative
Description: This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
Study: NCT02114073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: In control arm, betamethasone eye drop will be prescribed in postoperative period.
Study: NCT03858309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Group 1
Description: The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Group 2
Description: The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
Study: NCT04749992

Intervention type: PROCEDURE
Intervention: Polysomnographic examination in sleep laboratory (PSG measurement)
Description: Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.

Intervention type: PROCEDURE
Intervention: Polysomnographic examination in sleep laboratory (PSG measurement)
Description: Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
Study: NCT02575157

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention
Study: NCT04249986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Borg Rating of Perceived Exertion
Description: Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Borg Rating of Perceived Exertion
Description: Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
Study: NCT02891135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLATE
Description: Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
Study: NCT03420352

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thromboelastography
Description: paired TEG analysis undertaken from participants with the two different needles

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thromboelastography
Description: paired TEG analysis undertaken from participants with the two different needles
Study: NCT01103193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil injected
Description: mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane in step up concentration
Description: of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
Study: NCT00946387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
Study: NCT00925457

Intervention type: OTHER
Intervention: No Intervention
Description: Neither current domperidone nor current PPI

Intervention type: DRUG
Intervention: Current Domperidone
Description: Current domperidone at any dose, regardless of proton pump inhibitor status

Intervention type: DRUG
Intervention: Current proton pump inhibitor (PPI)
Description: Current PPI and not current dapoxetine
Study: NCT03855059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This will be a saline solution of given IV or perineural.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: This will be the active drug solution given IV or perineural.
Study: NCT04847336

Intervention type: OTHER
Intervention: No intervention is planned
Description: No intervention is planned

Intervention type: OTHER
Intervention: No intervention is planned
Description: No intervention is planned
Study: NCT00573300

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Single blood draw

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Single blood draw
Study: NCT00060840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: 40 ppm of Nitric Oxide continuously administered for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Nitrogen (N2) administered at 40 ppm for 48 hours
Study: NCT02740452

Intervention type: DEVICE
Group type: OTHER
Intervention: ligamys technique
Description: Ligamys technique (device) or standard technique

Intervention type: OTHER
Group type: OTHER
Intervention: standard technique (anatomic reconstruction)
Description: Ligamys technique (device) or standard technique
Study: NCT00691834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of unfractionated bone marrow mononuclear cells
Description: Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plasma and culture medium (10 ml)
Study: NCT01688349

Intervention type: OTHER
Group type: OTHER
Intervention: analyze the role of glucocorticoid in AT distribution.
Description: The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.

Intervention type: OTHER
Group type: OTHER
Intervention: analyze the role of glucocorticoid in AT distribution.
Description: The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analyze the role of glucocorticoid in AT distribution.
Description: The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.
Study: NCT04178785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
Study: NCT01681719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBV and Resistance
Description: use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistance & sham WBV
Description: used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBV & resistance sham
Description: used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.
Study: NCT04478006

Intervention type: GENETIC
Intervention: RNA-seq
Description: Gene expression and fusion transcripts analysis

Intervention type: GENETIC
Intervention: whole exon sequencing
Description: Genetic alternation analysis

Intervention type: OTHER
Intervention: Cytogenetics test
Description: Remission and relapse are monitored by cytogenetic analyses.
Study: NCT00670306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Pamoate
Description: Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
Study: NCT02127697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 capsules for inhalation, delivered via Concept1 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237
Description: Placebo to NVA237 delivered via Concept1 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol/ albuterol
Description: Taken as rescue medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: salbutamol/ albuterol
Description: Taken as rescue medication
Study: NCT05637580

Intervention type: DRUG
Intervention: Timing of drug administration
Description: The effect of drug administration timing on tumor and lymph node responses was observed.

Intervention type: DRUG
Intervention: Timing of drug administration
Description: The effect of drug administration timing on tumor and lymph node responses was observed.
Study: NCT02458326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Training
Description: 10 minutes of heating on the treadmill with a low speed that does not cause patient effort
Study: NCT03702283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penicillin Allergic Risk Stratification Best Practice Alert
Description: Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
Study: NCT03097809

Intervention type: OTHER
Intervention: SEEG Recordings
Description: To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing